(Reuters) -The U.S. Food and Drug Administration said on Monday it had approved Gamida Cell Ltd’s cell therapy to reduce the risk of infection in blood cancer patients.
Gamida Cell’s shares were up more than 40% at $1.14.
The company declined to comment on the therapy’s pricing.
(Reporting by Pratik Jain and Raghav Mahobe in Bengaluru; Editing by Shinjini Ganguli)
